PHENYTOIN - EEG EFFECTS AND PLASMA-LEVELS IN VOLUNTEERS

被引:34
作者
FINK, M
IRWIN, P
SANNITA, W
PAPAKOSTAS, Y
GREEN, MA
机构
[1] Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook, Long Island Research Institute, Stony Brook, NY
[2] Department of Neurology, Cornell University Medical College, New York, NY
[3] Institute for Neurophysiopathology, Genoa
关键词
EEG effects; Pharmacodynamics; Phenytoin; Plasma levels;
D O I
10.1097/00007691-197901000-00010
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The EEG and behavioral effects of oral doses of phenytoin from 100 mg to 1 g in normal male volunteers were measured. The EEG exhibited decreases in power in the slow frequencies and increases in the fast frequencies, accompanied by an increase in mean frequency. These changes are similar to those seen with psychostimulants. They occurred at average plasma levels of 8 .mu.g/ml and above. The time course and the intensity of EEG effects parallel plasma levels. Drug-related EEG changes were bilaterally symmetric. EEG changes at plasma levels of 8-12 .mu.g/ml were not associated with behavioral toxic signs. Future psychiatric studies of phenytoin as a psychostimulant should include monitoring for plasma levels, with a minimum of 8 .mu.g/ml as a guide to clinical efficacy.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 39 条
[31]  
Haward L., Drugs and concentration: Cognitive effect of DPH, Portsmouth J Psychol, 1, pp. 3-5, (1968)
[32]  
Stephens J.H., Shaffer J.W., A controlled replication of the effectiveness of diphenylhydantoin in reducing irritability and anxiety in selected neurotic outpatients, J Clin Pharmacol, 13, pp. 351-356, (1973)
[33]  
Klein D.F., Greenberg I.M., Behavioral effects of diphenylhydantoin in severe psychiatric disorders, Am J Psychiatr, 124, pp. 847-849, (1967)
[34]  
Kanzler M., Malitz S., Higgins J.C., How effective are antidepressants?, JAMA, 204, (1968)
[35]  
Lefkowitz M.M., Effects of diphenylhydantoin on disruptive behavior: Study of male delinquents, Arch Gen Psychiatry, 20, pp. 643-651, (1969)
[36]  
Case W.G., Rickeis K., Bazilian S., Diphenylhydantoin in neurotic anxiety, Am J Psychiatry, 126, pp. 254-255, (1969)
[37]  
Glazko A.J., Chang T., Diphenylhydantoin: Absorption, distribution, and excretion (continued), Anliepileptic Drugs, pp. 127-136, (1972)
[38]  
Lund L., Alvan G., Berlin A., Alexanderson B., Pharmacokinetics of single and multiple doses of phenytoin in man, Eur J Clin Pharmacol, 7, pp. 81-86, (1974)
[39]  
Reynolds E.H., Chadwick D., Galbraith A.W., One drug (Phenytoin) in the treatment of epilepsy, Lancet, 1, pp. 923-926, (1976)